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The validity and internal structure
of the Bipolar Depression Rating Scale:
data from a clinical trial of N-acetylcysteine
as adjunctive therapy in bipolar disorder
Berk M, Dodd S, Dean OM, Kohlmann K, Berk L, Malhi GS. The validity
and internal structure of the Bipolar Depression Rating Scale: data from a
clinical trial of N-acetylcysteine as adjunctive therapy in bipolar disorder.
Background: The phenomenology of unipolar and bipolar disorders differ
in a number of ways, such as the presence of mixed states and atypical
features. Conventional depression rating instruments are designed to
capture the characteristics of unipolar depression and have limitations in
capturing the breadth of bipolar disorder.
Method: The Bipolar Depression Rating Scale (BDRS) was administered
together with the Montgomery Asberg Rating Scale (MADRS) and Young
Mania Rating Scale (YMRS) in a double-blind randomised
placebo-controlled clinical trial of N-acetyl cysteine for bipolar disorder
(N = 75).
Results: A factor analysis showed a two-factor solution: depression and
mixed symptom clusters. The BDRS has strong internal consistency
(Cronbach’s alpha = 0.917), the depression cluster showed robust
correlation with the MADRS (r = 0.865) and the mixed subscale
correlated with the YMRS (r = 0.750).
Conclusion: The BDRS has good internal validity and inter-rater
reliability and is sensitive to change in the context of a clinical trial.
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Introduction
Scales that were developed for use in unipolar
depression to measure depression severity are regu-
larly used to measure depression in bipolar disorder.
Depressive episodes of bipolar disorder have a dif-
ferent phenomenology to the episodes of unipolar
depression (1). However, there is also considerable
overlap of symptoms as well as heterogeneity of
depressive phenomenology within the two diagnostic
categories.
Features of bipolar depression can include abrupt
onset and offset and atypical features such as fatigue,
hypersomnia, hyperphagia and rejection sensitivity.
Depressive episodes may be more recurrent in bipo-
lar depression than in unipolar depression and may
occur at an earlier age of onset; there may also be
features of irritability, mixed states, lability, feelings
of worthlessness, unvarying mood and marked anhe-
donia (2). In clinical studies of bipolar depression,
the most widely used observer-rated scales are the
Hamilton Depression Rating Scale (HAM-D) (3) and
the Montgomery A˚sberg Depression Rating Scale
(MA˚DRS) (4). Although they are useful instruments,
both instruments were developed for use in pop-
ulations with unipolar depression. Given that the
phenomenology and clinical characteristics of bipo-
lar and unipolar depressions differ (5), a rating scale
more sensitive to the features of bipolar depression
is required.
The Bipolar Depression Rating Scale (BDRS) is an
observer-rated scale for bipolar depression. It can be
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downloaded free of charge from www.barwonhealth.
org.au/bdrs. It was designed to reflect the charac-
teristics of bipolar depression and uses items that
partially overlap and partially differ from items in
the HAM-D and MA˚DRS. For example, the BDRS
includes both insomnia and hypersomnia as char-
acteristic of depression rather than insomnia only
and both hyperphagia and hypophagia rather than
hypophagia only. The BDRS additionally includes
items that characterise mixed states. The BDRS
places a different emphasis on items compared to
the HAM-D and MA˚DRS which better reflects bipo-
lar depression. In a study where bipolar patients
(N = 60) were administered, the BDRS hierarchical
cluster analysis (HCA) and multidimensional scal-
ing (MDS) revealed an internal structure that was
sensitive to complex features of bipolar depression.
The BDRS was found to have a two-cluster structure,
with 12 items in a depressive symptoms cluster and
8 items in a mixed symptoms cluster (6).
Other rating scales designed specifically for use
in bipolar disorder, most notably the Young Mania
Rating Scale (YMRS), focus on manic and hypo-
manic symptoms. The BDRS is the only validated,
freely available scale for use in bipolar depression.
The scale was first published in 2007 (7) and is being
used in several clinical studies and is currently avail-
able in seven languages. The purpose of this paper
is to assess the validity of the BDRS as an outcome
measure in a clinical trial. The results of the trial,
including change in BDRS scores, are reported else-
where (8). This is the first completed and published
clinical trial where the BDRS has been used as an
outcome measure.
This paper reports on the analysis of validity of the
BDRS both within items and compared to the YMRS,
MA˚DRS and HAM-D in a clinical trial population.
Method
In a 24-week double-blind, randomised clinical trial
of N-acetylcysteine or placebo for the treatment of
depressive symptoms in bipolar disorder, the BDRS
was administered to all participants at each of the
nine study visits from baseline, assessment visits
during the 24-week trial and a discontinuation assess-
ment after a further 4-week washout period. A diag-
nosis of bipolar I or II disorder was confirmed
using the Mini International Neuropsychiatric Inter-
view (9). There were three trial clinicians who con-
ducted the interviews at three different sites. Trial
clinicians were trained together at a training session
prior to commencing the clinical trial in order to
ensure proficiency in administering the BDRS and
to minimise the differences in scoring between the
raters. Only visit 1 data are used in this scale valida-
tion study.
Statistical methods
Factor analyses. Exploratory factor analyses (EFA)
were conducted using the unweighted least squares
method. Squared multiple correlations were specified
as the prior communality estimates and an oblique
(Promax) factor rotation was used as dimensions
were expected to be correlated. Factors were retained
after assessment of the Scree test, the proportion of
common variance accounted and the interpretability
criteria.
Reliability analyses. Internal consistency reliabil-
ity was assessed by calculating correlations between
each of the 20 items of the BDRS using Cron-
bach’s alpha.
Hierarchical cluster analysis. HCA was performed
using Ward’s minimum-variance method with the
emerging cluster being determined by the least
increase in the sum of squared Euclidean distance.
Multidimensional scaling. MDS was considered as
an alternative to the EFA where similarities or
dissimilarities (distances) between the items on the
BDRS were investigated. In order to select the
optimal number of dimensions, the Scree test and
the interpretability of configuration were used. In
addition, the S-Stress level (Stress) was used as a
badness-of-fit measure and the R2 index (RSQ) as a
goodness-of-fit measure, both of which range from
0 (perfect fit for the Stress; worst possible fit for
the RSQ) to 1 (worst possible fit for the Stress;
perfect fit for the RSQ). The Stress <0.2 or RSQ
>0.6 is generally acceptable in terms of the data
interpretability and information loss (10,11).
Associations between measures. Associations
between the BDRS and the YMRS, MA˚DRS and
HAM-D were assessed using Pearson correlations.
All statistical analyses were performed using
SAS® Version 9.1.3 for Windows™ (SAS Institute,
Cary, North Carolina, USA).
Results
A total of 75 participants were randomised and
included in the efficacy analyses; however, 76 par-
ticipants underwent visit 1 assessments (1 withdrew
following the baseline visit), therefore N = 76 at
visit 1.
Table 1 shows the factor loadings and the correla-
tions of each individual item with the total BDRS
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score. The two-factor solution was deemed to be
most suitable for this set of data explaining 82% of
the variance. In each column, the items with high
factor loadings are shown in bold. Two factors were
identified. Items 1–16 corresponded to one factor
labelled depression and items 17–20 corresponded to
a second factor labelled mixed states. Factor loadings
are given in Table 1. These results are very simi-
lar to those reported in the original validation of the
BDRS (7) which identified three factors: psycholog-
ical depression corresponding to items 1–3 and 5–7,
somatic depression corresponding to items 4, 8–14
and 16, and mixed states corresponding to items 15
and 17–20.
The correlations of each item with the BDRS total
score are also shown in Table 1 and were significant
at the 0.05 level with the exception of item 18
(increased motor drive). This was consistent with
previous findings (7).
Strong internal consistency was observed with the
visit 1 Cronbach’s alpha coefficient 0.905 (raw) and
0.903 (standardised).
Pearson correlations between the two factors and
the BDRS, HAM-D, Montgomery Asberg Rating
Scale (MADRS) and YMRS totals are shown in
Table 2. The correlation coefficient between the
BDRS and the MADRS was strong and positive with
a value of 0.87. The correlation of the depression
subscale (items 1–15) of the BDRS with the
MADRS was high, 0.86. The total BDRS scores, as
expected, correlated weakly with the YMRS (0.26),
Table 1. Rotated factor pattern (standardised regression coefficients) for visit 1
Variable Label
Depression
factor 1
Mixed states
factor 2
Item-total
correlations
B1 Depression 0.743 −0.164 0.611
B2 Sleep disturbance 0.180 0.198 0.286
B3 Appetite disturbance 0.269 0.051 0.295
B4 Social impairment 0.761 0.003 0.695
B5 Activity/energy
reduction
0.771 −0.010 0.692
B6 Reduced motivation 0.863 −0.103 0.736
B7 Reduced
concentration
0.733 −0.087 0.648
B8 Anxiety 0.429 0.044 0.429
B9 Anhedonia 0.915 0.015 0.835
B10 Flattened affect 0.747 −0.025 0.668
B11 Worthlessness 0.812 0.015 0.745
B12 Helplessness 0.637 0.178 0.642
B13 Suicidal ideation 0.701 0.304 0.759
B14 Guilt 0.643 0.050 0.590
B15 Psychotic symptoms 0.436 0.499 0.603
B16 Irritability 0.389 0.543 0.583
B17 Lability 0.248 0.578 0.478
B18 Increased motor drive −0.369 0.698 −0.034
B19 Increased speech −0.223 0.773 0.116
B20 Agitation 0.056 0.734 0.373
Table 2. Pearson’s correlation between scales based on the two factors (depression
and mixed) and the BDRS, HAM-D, MADRS and YMRS totals
Factors Depression Mixed BDRS total†
BDRS total 0.954∗ 0.594∗ –
BDRS total (minus items from factor) 0.331∗∗ 0.325∗∗ –
MADRS total 0.865∗ 0.428∗ 0.870∗
YMRS total 0.031 0.750∗ 0.264∗∗
†Scales formed by summing items with high loadings as given in Table 1.
∗p < 0.001, ∗∗p < 0.05.
while the mixed subscale items (items 16–20) were
more strongly correlated with the YMRS (r = 0.75).
The correlation between the two factors was 0.33.
Figure 1 shows the presence of a two-cluster
structure for the BDRS. The levels of dissimilar-
ity between items, as measured by the semi-partial
R2, on the horizontal distance are shown. Cluster
1 includes 13 items of depressive symptoms and is
almost entirely consistent with the exploratory fac-
tor analyses, apart from the inclusion of the somatic
item of sleep disturbance and the exclusion of the
suicidal ideation. The second cluster includes seven
items of mixed symptoms. Findings were similar to
Chang et al. (6).
Figure 2 shows the two-dimensional (depression
and mixed clusters) scatter plot of the MDS solutions
for the items of the BDRS. The 2D solution was sup-
ported by the stress and R2 measures and was con-
sistent with the two-factor solution of the exploratory
factor analyses. The cluster of items depicted for both
the depression and mixed states closely related to
what was observed for the EFA factor loadings.
Discussion
Validation data from participants in the clinical trial
were consistent with what was previously reported in
the original validation of the BDRS conducted in a
patient cohort (7). Cronbach’s alpha coefficient was
very similar to the score of 0.917 reported in the ear-
lier study. The two-factor solution reported in this
study overlapped closely with the three-factor solu-
tion reported in the earlier study (7) and was similar
to the two-factor solution of Chang et al. (6). Depres-
sive and mixed clusters have been clearly identified
in all three studies. The depressive cluster was fur-
ther divided into depressive (somatic) and depressive
(psychological) clusters in the earlier study (7). Both
MDS and HCA revealed consistent results with EFA
and confirmed findings from previous work.
In the context of the trial, the BDRS was simple to
administer, time effective and was useful and sensi-
tive for severity of depression in bipolar disorder and
was sensitive to change. It worked well within the
battery of outcome measures administered to study
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Fig. 2. Representation of the relationship of the two dimensions (depressive cluster and mixed states cluster) between the 20 items
of the BDRS (N = 76) at baseline. The depressive cluster and mixed cluster are indicated by black dots and the white dots,
respectively. B1, depressed mood; B2, sleep disturbance; B3, appetite disturbance; B4, reduced social engagement; B5, reduced
energy and activity; B6, reduced motivation; B7, impaired concentration and memory; B8, anxiety; B9, anhedonia; B10, affective
flattening; B11, worthlessness; B12, helplessness and hopelessness; B13, suicidal ideation; B14, guilt; B15, psychotic symptoms;
B16, irritability; B17, lability; B18, increased motor drive; B19, increased speech; B20, agitation.
participants by trial clinicians at interview. It com-
pares well with the HAM-D and MA˚DRS for ease of
administration and time to administer. A significant
difference in BDRS score between N-acetylcysteine
and placebo treated participants was measured at 24
weeks (p = 0.012) (8), confirming the usefulness of
the BDRS in the clinical trial. The scale appeared to
be sensitive to change.
Conclusion
The BDRS has been shown to have internal con-
sistency and to be a useful measure to assess the
outcomes of clinical studies of bipolar disorder. It
has been shown to accurately measure the severity
of bipolar depression. It is a simple scale to admin-
ister, is time effective and allows for high levels
of inter-rater reliability. The BDRS is sensitive to
change and given its high correlation to the MADRS
and HAM-D (currently the most wide-spread primary
outcome measures for bipolar depression) is suitable
as a primary or secondary outcome measure in clin-
ical studies of bipolar depression.
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